Sign in to view content

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen

Michael J Allingham, MD, PhD

Video
Published 2019

Michael J. Allingham, MD, PhD

AMD Non-neovscular Symposium

Related

Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Updates from the Field
2022
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Updates from the Field
2019
Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2022

Category: AMD-Non-Neovascular

See more